Is the standardized phase angle a predictor of short- and long-term adverse cardiovascular events in patients with acute myocardial infarction? A cohort study

Queiroz, Sandra Azevedo; González, Marı́a Cristina; Silva, Alana Monteiro Bispo da; Costa, Jálissa Karla de Araújo; Oliveira, Carlos Diego Ramos de; Sousa, Iasmin Matias de; Fayh, Ana Paula Trussardi

doi:10.1016/j.nut.2022.111774

Cited by 6 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An individual standardized PhA (SPhA) value was determined from the sex‐matched and age‐matched value for the reference population by subtracting the reference PhA value from the PhA of the observed patient and then, dividing the result by the respective age‐reference and sex‐reference SD, that is, SPhA = ([measured PhA − mean population reference PhA] ÷ SD of the reference population PhA) 22 . The SPhA was chosen because this indicator produce better results than raw PhA values to identify high‐risk individuals, 23,24 and a previous study of our research group showed that the SPhA was an independent predictor of an increased length of hospital stay in this population 8 …”

Section: Methodsmentioning

confidence: 99%

“…6 Malnourished ones have an increased risk of adverse clinical outcomes, prolonged length of stay (LOS), and hospital readmission. [6][7][8][9] Although studies about the body composition (BC) of hospitalized patients have increased in the recent years, there are difficulties in evaluating patients post-AMI regarding measurements due to their particularities (the need for hospitalization in an intensive care unit [ICU] and early intervention, large volume of intravenous medications, fluid retention and changes in hydration status, inflammation, and physical limitations), 9,10 and there is no criterion-standard method for this diagnostic.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioelectrical impedance vector analysis is different according to the comorbidity burden in post–acute myocardial infarction

Lopes,

Sousa,

Queiroz

et al. 2023

Nut in Clin Prac

Self Cite

View full text Add to dashboard Cite

BackgroundThe prevalence of a high comorbidity burden in patients who suffered an acute myocardial infarction (AMI) is increasing with the aging population, and the nutrition status also may be a predictor of clinical outcomes for these patients. This study aimed to investigate the relationship between the comorbidity burden and the characteristics of the bioelectrical impedance vector analysis (BIVA) in patients post‐AMI.MethodsThis prospective observational cohort study was conducted with adult patients who were hospitalized with AMI. Pre‐existing comorbidities were assessed by the Charlson comorbidity index (CCI) adjusted by age, and anthropometric and BIVA characteristics were evaluated after the hemodynamic stabilization. All patients were followed‐up until hospital discharge, and their length of stay was observed.ResultsA total of 184 patients (75% were males; mean age, 60.2 ± 12.3 years) were included. The most common comorbidities were dyslipidemia (73.9%), hypertension (62%), and type 2 diabetes (34.2%). A higher CCI (≥3) was associated with sex (P = 0.008) and age (P < 0.001). Regarding BIVA, statistically significant differences were detected between sex (P < 0.001), age (P < 0.001), and CCI (P = 0.003), with longer vectors in female, older adults, and those with CCI ≥ 3.ConclusionFinding a relationship between BIVA and CCI suggests the first identified coherent differences, potentially correlated with diseases, representing a first contribution to support this type of assessment. Therefore, with BIVA, healthcare professionals may monitor abnormalities and adopt preventive nutrition care measures on patients post‐AMI to improve their clinical status.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bioelectrical impedance vector analysis is different according to the comorbidity burden in post–acute myocardial infarction

Lopes,

Sousa,

Queiroz

et al. 2023

Nut in Clin Prac

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, with increasing age, the risk of the patient developing sarcopenia increases [ 7 ], resulting in negative effects, including falls, fractures, functional disability, enhanced hospital admission rates, reduced quality of life, and even death [ 8 ]. Some studies have also reported a relationship between muscle mass parameters and adverse outcomes in post-AMI patients [ 9 , 10 ] and other cardiovascular conditions [ 11 , 12 ]. Therefore, screening sarcopenia is pivotal in this population.…”

Section: Introductionmentioning

confidence: 99%

“…The SARC-F was developed in 2013 [ 13 ] and screens patients at risk for sarcopenia, which includes deficiencies in strength, walking, rising from a chair, climbing stairs, and experiencing falls. Each of the self-reported parameters receives a specific score (from 0 to 2), with the greatest maximum SARC-F score being 10 [ 10 , 13 , 14 ]. Although the accuracy of this questionnaire has mainly been verified in healthy people living in the community [ 14 , 15 ] and in patients with cancer [ 16 , 17 , 18 ], few studies have been conducted on patients with CVD.…”

Section: Introductionmentioning

confidence: 99%

SARC-F Is a Predictor of Longer LOS and Hospital Readmission in Hospitalized Patients after a Cardiovascular Event

et al. 2022

Self Cite

View full text Add to dashboard Cite

It is already established that sarcopenia is associated with adverse outcomes; however, few studies have focused on patients who have suffered an acute cardiovascular event. The use of SARC-F, a 5-item sarcopenia screening questionnaire, in these patients remains to be investigated. We aimed to investigate whether SARC-F can predict adverse outcomes in patients admitted to a hospital with a suspected infarction. This is a 1-year prospective cohort study. During hospitalization, patients completed the SARC-F questionnaire (scores ≥ 4 considered positive for the risk of sarcopenia). Length of hospital stay (LOS), new hospital admission, myocardial infarction, and cardiovascular mortality were collected via medical records and phone interviews. In total, 180 patients were evaluated. The median age was 60.6 years; 72.3% of the participants were men, and half of the sample had comorbidities. The median SARC-F score was 1.0 (interquartile range, 0–3.0), and 21.1% of the participants screened positive. Risk of sarcopenia was independently associated with longer LOS (odds ratio, 2.34; 95% CI, 1.09–5.04; p = 0.030) and hospital readmission (odds ratio, 3.73; 95% CI, 1.60–8.69; p = 0.002). One-fifth of post-acute cardiovascular event patients in this cohort screened positive for sarcopenia using the SARC-F screening questionnaire. Positive scores were associated with a longer LOS and hospital readmission.

show abstract

“…Nevertheless, data on cardiovascular diseases are scant, while even more rare is information about the clinical and prognostic impact of PhA within HF. Queiroz et al [16] outlined the role of PhA in predicting hospital length-of-stay in patients with acute myocardial infarction rather than foreseeing major adverse cardiac events (MACE). In patients with HF, PhA might be considered as a reliable tool for physicians who are involved in the daily management of this pathology [17][18][19].…”

mentioning

confidence: 99%

The role of bioelectrical phase angle in patients with heart failure

Scicchitano¹,

Massari²

2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

The most challenging feature of heart failure (HF) still remains the evaluation of congestion. Residual congestion at discharge and the difficulties in perfectly dosing therapies in order to balance the hydration status of the patient are the most worrisome issues when dealing with HF. The use of bioimpedance vector analysis (BIVA) might promote a different approach in the general management of patients with HF. BIVA is a reliable, fast, bedside tool able to assess the congestion status. It proved to be helpful to physicians for diagnosing congestive status, managing therapies, and providing prognostic information in the setting of HF. Bioelectrical Phase Angle (PhA) – as derived from equations related to the parameters of BIVA – recently surged as a possible biomarker for patients with HF. Studies provided data about the application of PhA in the clinical management and in the overall risk stratification of HF patients. Basically, the use of PhA might be considered as a holistic evaluation of patients with HF which includes the need for a multiparametric approach able to effectively depict the clinical status of patients. There is no definite biomarker able to comprehensively describe and identify all the features of HF patient, but scores based on molecules/techniques able to explore the different pathogenetic mechanisms of HF are desirable. The aim of this review was to provide a comprehensive evaluation of literature related to PhA role in HF and the impact of this biomarker on clinical management and risk stratification of HF patients.

show abstract

Is the standardized phase angle a predictor of short- and long-term adverse cardiovascular events in patients with acute myocardial infarction? A cohort study

Cited by 6 publications

References 31 publications

Bioelectrical impedance vector analysis is different according to the comorbidity burden in post–acute myocardial infarction

Bioelectrical impedance vector analysis is different according to the comorbidity burden in post–acute myocardial infarction

SARC-F Is a Predictor of Longer LOS and Hospital Readmission in Hospitalized Patients after a Cardiovascular Event

The role of bioelectrical phase angle in patients with heart failure

Contact Info

Product

Resources

About